Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Goodwill & Intangibles (2016 - 2025)

Gsk has reported Goodwill & Intangibles over the past 11 years, most recently at $31.6 billion for Q4 2025.

  • Quarterly results put Goodwill & Intangibles at $31.6 billion for Q4 2025, up 9.48% from a year ago — trailing twelve months through Dec 2025 was $31.6 billion (up 9.48% YoY), and the annual figure for FY2025 was $31.6 billion, up 9.48%.
  • Goodwill & Intangibles for Q4 2025 was $31.6 billion at Gsk, up from $28.9 billion in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for GLAXF hit a ceiling of $54.8 billion in Q4 2021 and a floor of $25.1 billion in Q4 2022.
  • Median Goodwill & Intangibles over the past 5 years was $28.9 billion (2024), compared with a mean of $33.4 billion.
  • Biggest five-year swings in Goodwill & Intangibles: plummeted 54.25% in 2022 and later grew 9.48% in 2025.
  • Gsk's Goodwill & Intangibles stood at $54.8 billion in 2021, then plummeted by 54.25% to $25.1 billion in 2022, then increased by 6.88% to $26.8 billion in 2023, then grew by 7.81% to $28.9 billion in 2024, then increased by 9.48% to $31.6 billion in 2025.
  • The last three reported values for Goodwill & Intangibles were $31.6 billion (Q4 2025), $28.9 billion (Q4 2024), and $26.8 billion (Q4 2023) per Business Quant data.